Alcon Releases Clareon IOLs in the U.S.

Alcon has launched its new Clareon intracoluar lenses (IOLs) in the U.S. Clareon IOLs feature proprietary “glistening-free” material with very low haze and subsurface nanoglistenings (SSNGs).
 
“We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” Ian Bell, president, Global Business & Innovation, Alcon, told the press. “Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.”
 
The lens edge helps reduce glare and posterior capsular opacification, and STABLEFORCE haptics improve axial and rotational stability. Clareon has been the subject of 30 published studies and the Clareon monofocal and toric IOLs have been implanted in over a million eyes, according to the company.
 
The Monarch next-gen, reusable IV delivery system was designed for the new Clareon material.
 
“As one of the investigators for the Clareon pivotal trial, I was immediately impressed with the clarity of the new IOL material, delivery system and the consistent refractive outcomes,” said Dr. Samuel H. Lee, MD, Ophthalmologist, Sacramento, Calif. “Today, the clarity of Clareon persists four years later in my trial patients, with the optic performance that I expect from Alcon IOLs, as well as continued high patient satisfaction.”
 
Alcon expects to release Clareon Toric in the U.S. later this year, and roll out Clareon IOLs in international markets throughout this year and next.